Though intravenous thrombolysis has been shown to improve symptoms in acute ischemic stroke patients, the recanalization rate remains low (22.6%) and only around 30% of patients benefit from the treatment. Recently, endovascular thrombectomy using stent retrievers or catheters has proven to be more effective, with a success rate of nearly 80%. However, only 50% of patients experience clinical improvement, highlighting the need for new treatment strategies to enhance outcomes. Current guidelines recommend maintaining systolic blood pressure (BP) below 180 mmHg after thrombectomy, but there is a lack of evidence regarding optimal blood pressure management post-reperfusion.
Four randomized clinical trials, including the OPTIMAL-BP trial, have examined blood pressure control following thrombectomy. Meta-analyses showed that intensive BP lowering did not reduce symptomatic hemorrhage and was associated with worse functional outcomes at 3 months. Specifically, lowering BP too aggressively after successful reperfusion could worsen outcomes by reducing perfusion to the ischemic penumbra. Therefore, this study will investigate whether a more targeted blood pressure elevation strategy could improve patient prognosis compared to standard BP control in those with post-thrombectomy systolic BP below 140 mmHg.
This is a prospective, randomized, open-label trial with blinded endpoint assessment (PROBE) design, aimed at comparing intensive and standard BP control strategies in acute ischemic stroke patients. Participants will be randomized 1:1 into either an intensive BP control group (targeting a 20% systolic BP increase, capped at 180 mmHg) or a standard BP control group (systolic BP below 180 mmHg).

Start Date01 Dec 2024

Sponsor / Collaborator

Yonsei University

NCT06635707

/ Not yet recruitingNot ApplicableIIT

The Study on the Efficacy and Safety of Using Urapidil Alone or in Combination With Esmolol for the Treatment of Acute Hypertensive Intracerebral Hemorrhage: A Prospective, Open-label, Observational, Multicenter Research

The objective of this study is to investigate the efficacy and safety of urapidil monotherapy versus the combination of esmolol in treating participants with acute hypertensive intracerebral hemorrhage through a prospective, open-label, observational, multicenter clinical trial, aiming to provide guidance for clinicians in formulating rational treatment plans.

Start Date01 Nov 2024

Sponsor / Collaborator

Qianfoshan Hospital of Shandong Province

ChiCTR2500103753

/ Not yet recruitingNot ApplicableIIT

Cerebral oxygen saturation as a guide to optimize blood pressure management in elderly patients with MCI who are at high risk of developing PND

Start Date01 Oct 2024

Sponsor / Collaborator-

100 Clinical Results associated with Urapidil

100 Translational Medicine associated with Urapidil

100 Patents (Medical) associated with Urapidil

831

Literatures (Medical) associated with Urapidil

01 Dec 2025·European Journal of Trauma and Emergency Surgery

Urapidil as a neuroprotective agent: targeting hypoxia, inflammation, and oxidative stress in traumatic brain injury

Article

Author: Ozmen, Ozlem ; Bindal, Ahmet ; Imeci, Orhan ; Tepebasi, Muhammet Yusuf ; Sevuk, Mehmet Abdulkadir ; Yildirim, Burak ; Asci, Halil ; Karabacak, Pınar ; Ilhan, Ilter

Abstract:

Purpose:

One of the important causes of morbidity and mortality in the world is traumatic brain injury (TBI), which is a process that triggers damaging mechanisms such as inflammation, oxidative stress, and apoptosis. The results of current pharmaceutical methods are not enough, and researches into new therapy modalities are needed. This study aimed to evaluate the neuroprotective effects of Urapidil (Ura), which is an alpha-1 adrenergic receptor antagonist with serotonergic activity, in a TBI model and investigating signaling pathways like high mobility group box 1 (HMGB1), BCL2-interacting protein 3-like (BNIP3L), and hypoxia-inducible factor-1 alpha (HIF1α).

Methods:

Thirty-two rats were divided into four groups: control, TBI, TBI + Ura0.5 (0.5 mg/kg), TBI + Ura5 (5 mg/kg) groups. Tissue integrity and expressions of tumor necrosis factor-alpha (TNF-α), caspase-3 (Cas-3), tyrosine hydroxylase (TH), HIF1α, BNIP3L, and HMGB1 were assessed. Ura’s biochemical oxidative stress indicators were also assessed.

Results:

Ura treatment at both doses, significantly decreased histopathological findings, BNIP3L, HMGB1, and HIF1α expressions, TNF-α, Cas-3, TH immunexpressions, and TOS and OSI levels, and elevated TAS levels compared to TBI group. These results show that Ura regulates molecular pathways related to TBI, including neuroinflammation, mitochondrial dysfunction, and hypoxia.

Conclusion:

Ura shows promising tissue-protective effects in TBI by targeting inflammation, oxidative stress, and apoptosis. This study provides a new perspective on the need for further development of Ura for therapeutic use.

01 Nov 2025·International Journal of Surgery Case Reports

Noninvasive blood pressure measurements demonstrated a significant underestimation of blood pressure in a patient with severe preeclampsia: a case report

Article

Author: Yu, Chao ; Gu, Juan ; Zhang, Yan

INTRODUCTION AND IMPORTANCE:

Accurate diagnosis and management of preeclampsia rely on reliable blood pressure (BP) measurements. This report highlights a case where non-invasive BP monitoring underestimated maternal BP in a patient with severe preeclampsia.

CASE PRESENTATION:

At 27 weeks' gestation, a 33-year-old gravida 1, para 0 presented with blurred vision, diagnosed with chronic hypertension and preeclampsia, incomplete HELLP (elevated liver enzymes and lower platelet count syndrome), and abnormal umbilical artery Doppler. Magnesium sulfate and dexamethasone were administered for fetal lung maturity and maternal seizure prophylaxis. Oral labetalol, nitroglycerin, and urapidil were continuously infused to control non-invasive blood pressure (NIBP), and an emergency cesarean section was planned. Upon arrival in the operating room, left radial intra-arterial blood pressure (RIBP) was recorded as 190/112 mmHg, whereas the NIBP of the left arm was 155/105 mmHg. Intraoperative BP management was guided by RIBP. When the patient was transferred from the transport bed to the intensive care unit bed, the NIBP showed 120/70 mmHg, while the RIBP remained elevated at 180/110 mmHg. Subsequently, interventions including spasmolytic therapy, antihypertensive medications, and sedation were initiated, leading to a progressive reduction in the discrepancy between NIBP and RIBP.

DISCUSSION:

NIBP may underestimate actual BP in severe preeclampsia, particularly when maternal BP is poorly controlled. In these patients, invasive blood pressure monitoring may be useful for assessing rapid changes in cardiovascular status.

CONCLUSION:

NIBP may significantly under-estimated actual BP in severe preeclampsia patients with poorly controlled maternal BP. Further research is needed to assess its impact on outcomes.

01 Nov 2025·JOURNAL OF PHARMACEUTICAL SCIENCES

Compatibility and safety of vancomycin combined with Nicardipine, Nimodipine, and Urapidil in Microinfusion pump systems for clinical subarachnoid hemorrhage treatment

Article

Author: Li, Xiao ; Dong, Zhanjun ; Fan, Liju ; Yang, Haotian ; Peng, Shuaining

Subarachnoid hemorrhage (SAH) necessitates multi-drug therapy, yet compatibility data for vancomycin combined with nicardipine, nimodipine, and urapidil in microinfusion systems remain lacking. This study aims to assess their physicochemical stability and biosafety to support clinical co-administration. Compatibility solutions were prepared in microinfusion pumps and 0.9 % NaCl bags. Stability was evaluated via visual inspection, pH, insoluble particles, and drug content (validated HPLC). Biocompatibility was tested in human brain microvascular endothelial cells (HBMECs; viability, LDH, IL-6/TNF-α). Efficacy and safety were compared in a rat SAH model (neurological scores, blood pressure, cerebral edema, CSF drug penetration). Consequently, all solutions remained clear without precipitation for 8 h (pump) or 24 h (bag). pH (5.24-5.33) and particles met pharmacopeial standards. HPLC showed drug retention >98 % (vancomycin, nicardipine, urapidil) and >90 % (nimodipine, minimal adsorption in bags). HBMEC viability exceeded 95 %, with no significant LDH or cytokine elevation (P > 0.05). In SAH rats, combination therapy significantly improved neurological scores (P < 0.001) and reduced edema (P < 0.01) versus monotherapies, with equivalent efficacy/safety between infusion systems (P > 0.05). Nimodipine CSF penetration and vancomycin troughs were unaffected. In Conclusion, vancomycin exhibits excellent compatibility and safety with nicardipine, nimodipine, and urapidil in microinfusion systems. Both delivery methods are clinically equivalent within 24 h, enabling reliable multi-target SAH treatment.

News (Medical) associated with Urapidil

23 Dec 2020

·www.geneonline.com

China’s Hasten Biopharmaceutic Acquires Five Non-Core Assets from Japan’s Takeda

Continuing its divestiture strategy since January 2019, Takeda has planned on releasing non-core assets to focus on creating innovative therapies and developments on Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies, Oncology, and Neuroscience, the 5 chosen areas that are essential to its long-term growth strategy. After the divestiture with Celltrion in early December, Takeda struck up another deal with Hasten Biopharmaceutic, a company funded by Feidong County of Hefei City, China and established by Ray Capital Management Limited. Takeda is letting go of five prescription drugs, including cardiovascular and metabolism products that are mainly sold in China in exchange for around 322 million. The portfolio of select drugs generated 109.5 million net sales in 2019, mostly contributed by cardiovascular drug Ebrantil, one of the products sold to Hasten. As per the contract, the employees who are dedicated to the commercial support of these products will also be transferred to Hasten. As for the manufacturing and supply agreement, Takeda will continue to manufacture and supply the divested products to Hasten. The agreement is estimated to close by June 30, 2021, and until then, Takeda will have the full right of these products. For future use of proceeds, Takeda will firstly reduce its debt and then facilitate the R&D and expand its manufacturing capacity of these five core business areas. “This announcement marks continued progress on our commitment to simplify our global portfolio and remain focused on investing in our growth drivers, and research and development pipeline,” said Costa Saroukos, Chief Financial Officer, Takeda. “We remain committed to expansion in China with more than 15 planned approvals over the next five years. By continuing to execute and deliver on Takeda’s financial commitments, including paying down debt and focusing on our highly innovative portfolio, we can sustain our long-term growth and continue to deliver life-transforming treatments for patients worldwide.” For the past two years, Takeda has exceeded its $10 billion non-core asset divestiture target. Here are some of the divestiture agreements in 2020. March 2: Sold 30 prescription pharmaceuticals and over-the-counter (OTC) products in Near East, Middle East, and African countries within its Growth and Emerging Markets Business Unit (GEM BU) to Acino for 200 million March 2: Sold 18 select OTC and prescription pharmaceutical assets in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama, and Peru to Hypera Pharma for 825 million March 4: Sold 20 OTC and prescription pharmaceutical products exclusively in Russia, Georgia, and several countries from within the Commonwealth of Independent States to STADA Arzneimittel AG for 660 million. April 24: Sold 110 select OTC and prescription pharmaceutical assets in Europe to Orifarm for 670 million September 8: Sold non-core prescription pharmaceutical products sold predominantly in Europe and Canada to Cheplapharm for 562 million. December 1: Sold 18 pharmaceutical products and OTC products in the Asia Pacific to Celltrion for 278 million.

Acquisition

100 Deals associated with Urapidil

External Link

KEGG	Wiki	ATC	Drug Bank
D01333	Urapidil	C02CA06	DB12661

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Dysuria	Japan	Kaken Pharmaceutical Co., Ltd.	11 Nov 1999
Urination Disorders	Japan	Kaken Pharmaceutical Co., Ltd.	30 Jun 1995
Hypertension	Japan	Kaken Pharmaceutical Co., Ltd.	20 Sep 1988

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis